BIO 2 BUSINESS
EVENT MANAGEMENT

BIOTECH OUTSOURCING STRATEGIES

19th & 20th June, Basel, Switzerland

SPEAKER PROGRAMME AND EVENT CONTENT

BASEL 2019

Discovery and CMC Outsourcing for Small Molecules and Biopharmaceuticals

BIOTECH OUTSOURCING STRATEGIES

BASEL 2019

19th & 20th June, Basel, Switzerland

Introducing Biotech Outsourcing Strategies BASEL 2019 (BOS BASEL 2019), the outsourcing focused conference and exhibition for the pharmaceutical R&D Community.

DISCOVERY OUTSOURCING

CMC OUTSOURCING SMALL MOLECULE

(primarily non-commercial)

CMC OUTSOURCING BIOLOGICS

5 PRINCIPAL COMPONENTS

PRESENTATIONS
(3 Tracks covering Discovery Outsourcing / CMC Outsourcing Small Molecule / CMC Outsourcing Biologic)

INTERNATIONAL EXHIBITION
Showcasing the best of international CROs and CMOs

1-TO-1 PARTNERING
Pre-arranged 1-to-1 meetings between Buyers and Suppliers

INFORMATION NETWORKING
During drinks receptions

POSTERS
Showcasing Industry Innovation

WHO SHOULD ATTEND BOS BASEL 2019

DISCOVERY R&D PROFESSIONALS THOSE INVOLVED IN THE FOLLOWING FUNCTIONS:

Biotech & Pharma: Target site identification & validation, discovery biology, discovery chemistry, pharmacology, DMPK, lead validation, lead optimisation, in vitro ADME,

From CROs and CMO: Business development, sales, marketing and corporate management functions

CMC R&D PROFESSIONALS THOSE INVOLVED IN THE FOLLOWING FUNCTIONS:

Biotech & Phrma: PR&D, scale up, drug substance manufacturing, analytical method development, drug product manufacturing, pre-formulation, formulation, outsourcing project managers, external manufacturing, programme managers, contracts managers, CMC procurement

From CROs and CMO: Business development, sales, marketing and corporate management functions

BOS BASEL 2019 FACTFILE

Years in Basel: 4th consecutive year | **Delegate Numbers:** +350 in 2018 | **1-to-1 Meetings Held 2018**:+ 900

Scope: Discovery & CMC Outsourcing

FEATURED PRESENTATIONS

Discovery

Dr. Christoph Rosenbohm, *Head of Discovery Operations, RNA Molecule Research (RMR), Pharma Research and Early Discovery (pRED), Roche Innovation Center Copenhagen (RICC)*

As Head of Discovery Operations, RMR Christoph is responsible for leading the Oligonucleotides synthesis, Pharmacology, and Screening Operations teams and as a member of the RMR-LT he participates in defining and setting the strategy for RMR.

Christoph holds a Master of Science and a Ph.D. in Organic Chemistry from the University of Southern Denmark (the lab of Prof. Jesper Wengel - one of the inventors of LNA). After his PhD, Christoph worked as a post-doctoral fellow at the Danish Technical Univerisity. In addition Christoph holds an executive MBA in Technology, Market and Organisation from Copenhagen Business School.

Christoph started his biotech career in Cureon as chemist with the task of synthesizing the LNA monomers. The company was later merged with Pantheco A/S to create Santaris Pharma A/S in 2003, where he become group leader for the chemistry team. Later the group was joined with CMC, Bioinformatics, PK and Pharmacolgy to form the Research Operation Department for which he became the director. A position he held until the acquisition by Roche in 2014.

Presentation Title: *On-boarding New Technologies into existing Discovery Outsourcing Partnerships.*

Dr Garry Pairaudeau, *Head of Hit Discovery, AstraZeneca*

Garry Pairaudeau is currently Head of Hit Discovery at AstraZeneca; the group comprising HTS, Comp Chem, Virtual screening and DEL is responsible for generating high quality starting points for AstraZeneca. In addition, the group works extensively with academic ceantherntres of excellence through open innovation and strategic collaborations with groups such as MRC, CRUK, Life Arc and many others to help support academic drug discovery.

Garry also chairs the Global Chemistry Leadership team in AstraZeneca responsible for chemistry strategy and has been particularly active in building Automation and Machine learning capabilities in addition to continuing to lead AZ Discovery chemistry outsourcing.

Garry obtained his PhD in chemistry from the University of Southampton in 1991, followed by post-doctoral work at UC Irvine California. He joined AstraZeneca in 1994 as a medicinal chemist and was part of the chemistry team that discovered Brilinta. He has experience leading projects through all phases of Drug Discovery contributing to multiple clinical candidates in the respiratory, inflammation and CV areas. He has a long standing interest in lead generation, hit identification and diversity screening. Prior to taking up his current position in 2012 he was Director of Chemistry for the cardiovascular group at Alderley Park.

Presentation Title: *Innovation in Hit Identification.*

Dr Silvia Fonquerna, *Head of Research Alliances, Almirall*

PhD from University of Barcelona and Post-doc at University of Sheffield with Prof V. Aggarwal.

Joined Almirall in 1998 as a member of the starting Combinatorial Chemistry Group. From 2000 to 2008 worked as chemistry program leader working on a variety of targets including GPCRs, enzymes, chemokines and ion channels in the Respiratory therapeutic area. Since 2009 promoted to Medicinal Chemistry Head of Section and Inhalation Team Leader of a multidisciplinary group devoted to the design of inhaled drugs. Since 2015 involved in Idea Generation Groups for developing incremental innovation and repositioning projects.

Worked in several strategic collaborative programs and in 2018 promoted to Head of Research Alliances of a group responsible for running collaborations with other Biotechs, CROs and academic groups, obtain public funding and coordinate open innovation initiatives.

Presentation Title: *Developing and implementing collaborative strategies in Discovery to harness innovation.*

CMC (Small Molecules)

Katrine Bonner, *Key Account Director with Externalisation Centre of Excellence for Pharmaceutical Development & Supply, GlaxoSmithKline*

Katrine is a Key Account Director with Externalisation Centre of Excellence for Pharmaceutical Development & Supply at GSK. She has 25 years' experience in the Pharmaceutical Industry, starting as Formulation Scientist at GSK, working within Project Management and Business Development roles for Contract Development Organisations providing small molecule Formulation, Analytical and Clinical trial supplies services. As well as a supplier of speciality excipients for modified release technologies and film coating where building and maintaining customer-supplier relationships and working as a product development partner was key to both customer and supplier business success. Returning to GSK in 2016 and leading the Technical team supporting the production of ViiV HIV and Novartis Oncology product portfolios at the Ware site for Global Product Supply before coming back to the realms of R&D outsourcing.

Dr Rudolf Hausmann, *VP Technical Development & Operations, Santhera Pharmaceuticals*

Rudolf Hausmann, originally from Kiel Germany, studied Pharmacy before his Ph.D. in Immunology. He has also a degree in Pharmaceutical Medicine from Basel University.

His career in the Pharmaceutical Industry started at Hoffmann La-Roche in Basel/ Switzerland and he held different positions in Galenical Production, Formulation Development and Project Leadership. He worked on numerous development projects from pre-Phase-I up to launch.

2005 he started at Santhera Pharmaceuticals, a Biotech company near Basel, Switzerland, which is focussed on Development and Commercialization of new medicines against Neuromuscular Diseases. In his position as Head Technical Development & Operations he is responsible for Technical Development from Phase-I to Phase-III and commercial manufacturing & supply. He is also involved BD&L activities and has additional responsibilities as Project Leader.

Presentation Title: *Flexibility and Agility in the transfer and scale-up of development and launch products.*

Andrea Calenne, *Senior Manager External Manufacturing, Biogen International*

Employed as Senior Manager External Manufacturing at Biogen International, Andrea is supplier relationship manager for the outsourced manufacture of injectable products (Biologicals and Oligonucleotides).

Over the past 15 years Andrea worked in multiple QA and External Manufacturing roles for CSL Behring, Bayer Healthcare and Biogen, managing a relevant number of manufacturing sites and a product portfolio including plasma derivatives, biologicals, as well as non-sterile pharmaceuticals distributed globally.

Starting his career in Corporate Quality Management within a Japanese automotive company (Bridgestone), Andrea developed his professional identity in an environment where outsourcing is key to product compliance as well as to the performance of the supply process.

Andrea holds a M.Sc. in Organic Chemistry from University La Sapienza in Rome, after graduation he completed a Master in Intellectual Property at the Italian Patent and Trade Mark Office. Andrea speaks Italian, English, French, Spanish and German.

Born 1972 in Rome (Italy) Andrea lives in Switzerland with his family since 2005. Andrea is Italian and Swiss national.

Presentation Title: *Developing a supplier governance model as part of an integrated supplier relationship strategy.*

CMC (Biologics)

Dr Ulrich Rümenapp, *Head of Launch Preparation and Co-ordination, Biological Development, Bayer Pharma*

Dr. Rümenapp is based in Wuppertal, Germany and working within the Biological Development organization of Bayer AG, where he is responsible for the transfer of Bayer's pipeline candidates (antibodies and antibody-drug-conjugates) to external manufacturing partners and regulatory submission and launch preparations.

Prior to working in Development, Dr. Rümenapp was Head of Biotech Projects in Product Supply Biotech at Bayer, where he was responsible for contract manufacturing partnerships in the field of biotechnological drug substances and drug products and interdisciplinary project management with the goal to ensure market supply.

Before it was acquired by Bayer, Dr. Rümenapp hold a similar position at Schering AG, and before that, he worked in the Production & Logistics department of Schering, where he was responsible for production aspects of in- and out-licensing deals, due diligences, and product acquisitions of small molecule products and biologics.

Dr. Rümenapp studied chemistry and holds a Ph.D. in biosciences. He worked several years in academic research in the field of signal transduction and as an assistant teacher in the field of general pharmacology.

Today, Dr. Rümenapp area of expertise is the set-up and management of external relationships for the development and supply of bio-pharmaceutical products. He has more than 15 years of experience in the bio-pharmaceutical industry.

Presentation Title: *Biologics Outsourcing: Preparing for Launch Readiness with your CMO Partner.*

Arjan Roozen, *Chief Technical Officer, Zelluna Immunotherapy*

Arjan Roozen joined Zelluna Immunotherapy in April 2018 and is responsible Zelluna's Manufacturing and Development strategy. Arjan has extensive experience in GMP manufacturing in the EU and US. The supply chain management from raw materials, GMP cell manufacturing for clinical and commercial supplies. Prior to joining Zelluna, Arjan served as VP GMP Solutions & Manufacturing at Cellectis, where he headed up the team responsible for the sourcing of the critical raw materials as well as the manufacturing of the gene modified cell therapy products. Additionally, he has previous valuable experience from the CDMO Pharmacell, recently acquired by Lonza, responsible for its operational activities. Arjan has a degree in microbiology with specialization in molecular microbiology.

Presentation Title: *TBC*

Kyle Blair, *Biologics Global Category Manager, Operations Procurement, AstraZeneca*

Kyle has more than 30 years' experience in the pharmaceutical industry. He began his career in Discovery Chemistry at Pfizer working on antibacterial agents including macrolides, fluoroquinolones, and semi-synthetic carbohydrate derivatives of the fermentation product Hygromycin A. During his time at Pfizer Kyle earned a Master's degree in Organic Chemistry from the University of Connecticut.

Beginning in 2002, Kyle joined the outsourcing arm of Pharmaceutical Development at Pfizer. After several years managing FTE collaborations in support of Discovery programs, he joined the late stage development group to manage contract manufacturing relationships in support of key late stage assets, notably Xeljanz and Xalkori.

Since 2011 Kyle has been part of the AstraZeneca Operations Procurement organization supporting external manufacture of biologics drug substance and drug product. In addition to Antibody-Drug Conjugates, Kyle currently supports external partnerships covering the manufacture of a broad spectrum of biopharmaceuticals including oncolytic virus, plasmid DNA, messenger RNA, monoclonal antibodies and fragments, microbial expression products, and peptides.

Presentation Title: *TBC*

Dr Thomas Wegge, *Senior Director of Analytical Sciences, Ascendis Pharma GmbH*

Presentation Title: *Creating a robust analytical development strategy powered by external partnerships*

Programme BOS 2019 - Day 1

Time	DISCOVERY OUTSOURCING	CMC OUTSOURCING SMALL MOLECULE	CMC OUTSOURCING BIOLOGICS
08.00 - 09.00		**Registration & Partnering**	
09.00 – 10.30	Chair: Dr Hayley Binch, Head of Medicinal Chemistry, F Hoffmann-La Roche Ltd *Discovery Room*	**Outsourcing Process & Strategy** Chair: Dr Anna Matranga, Principal, AMC Alliances & Consulting *Small Molecule and Plenary Room*	
09.00	**Drug Discovery: Collaborations between CROs and the Pharmaceutical Industry.** Dr Vicky Steadman, General Manager, Eurofins Selcia Drug Discovery	**Choosing the right CMO: models for strategic sourcing, outsourcing and selection of CMO.** Dr Helge Tippmann, Senior Category Manager, Novo Nordisk A/S	
09.30	**Cn-boarding New Technologies into existing Discovery Outsourcing Partnerships.** Dr Christoph Rosenbohm, Head of Discovery Operations, Roche Innovation Center Copenhagen	**Building a robust, risk based, supplier qualification process.** Gabriele Sassi, Non Clinical Outsourcing Manager, R&D Outsourcing Management, CHIESI FARMACEUTICI S.p.A.	
10.00	**Effective Supplier Relationship development through the Supplier Relationship Mapping.** Alessandro Fazio, Non Clinical Outsourcing Manager, Chiesi Farmaceutici S.p.A	**CMO flexibility re-designed.** Mr Felix Faupel, Head of Contract Manufacturing, Acino International (10.00am) **Selection, development and scale-up of sustainable manufacturing processes for active pharmaceutical ingredients.** Dr Peter Pöchlauer, Innovation Manager API, Patheon, by Thermo Fisher Scientific (10.15am)	
10.30 - 11.00		**Refreshments and partnering**	
11.00 - 12.00	**BOS Outsourcing Showcase – Poster Presentations showcasing innovation and excellence in Discovery Outsourcing Services & Technologies.** Chair: Dr Duncan Judd, CEO, Awridian *Discovery Room*	**BOS Outsourcing Showcase – Poster Presentations showcasing innovation and excellence in Small Molecule CMC Services & Technologies.** Chair: Dr David Elder,Principal Consultant, David P Elder Consulting *Small Molecule and Plenary Room*	**BOS Outsourcing Showcase – Poster Presentations showcasing innovation and excellence in Biologics CMC Services & Technologies.** Chair: Dr Lee Smith, CEO, GreyRigge/ Chief Technology Officer, Themis Biosciences *Biologics Room*
12.00 - 13.30		**Lunch & Partnering** Lunch Sponsor Legacy	
13.30 – 15.30	**Technical Operations Outsourcing – Target ID & Validation to Hit Identification.** Chair: Dr Laura Millichamp, Founder, InsideReg *Discovery Room*	**Technical Operations Outsourcing – Early Phase, Small Molecule.** Chair: Dr Paul Madeley, Managing Director, Synth-Isis *Small Molecule and Plenary Room*	**Technical Operations Outsourcing – Early Phase, Biologics.** Chair: Prof, Dr, Tudor Arvinte, CEO, Therapeomics Inc and University of Geneva - *Biologics Room*
13.30	**Discovery of New Targets for Rare Diseases - developing new therapies to cure ALS.** Dr Inez de Greef-van der Sandt, CEO, Treeway and Partner/Co-Founder, 3D-PharmXchange	**Lean delivery of a sulfoximine-based inverse RORγt agonist for topical administration.** Dr Craig Harris, Senior Expert Scientist API Synthesis, Galderma	**Optimised CMO partnerships to expedite early stage development of bispecific antibodies.** Dr Martin Hangler, CMC Project Manager, Genmab
14.00	**Innovation in hit and lead identification at AstraZeneca.** Dr Garry Pairaudeau, Head of Hit Discovery, AstraZeneca	**Evolving a large pharma approach to externalisation for small molecule product development.** Katrine Bonner, Key Account Director, Externalisation CoE, GlaxoSmithKline	**Creating a robust analytical development strategy powered by external partnerships.** Dr Thomas Wegge, Senior Director of Analytical Sciences, Ascendis Pharma
14.30	**Developing and implementing collaborative strategies in Discovery to harness innovation.** Dr Silvia Fonquerna Pou, Head of Department, Almirall	**Pharmaceutical development pathways for poorly soluble small molecules and opportunities for CDMO innovation.** Dr Alexandre Gil, Head of Drug Product Development, Sanofi	**Challenge and strategy for successful ADC external manufacture.** Kyle T Blair, Global Category Manager, Biologics, AstraZeneca
15.00	**How to fast-track healthcare innovation in the Basel region.** Dr Leonildo Delgado, Manager, Innovation and Sourcing, BaseLaunch	**The importance of understanding the solid form landscape of an API during early product development.** Mr Jonathan Loughrey, Head of Screening Services, Cambrex	**Security of supply: choose a dedicated analytical partner to ease CMC capacity constraints.** Dr Ray Sexton, Business Development Manager, Solvias
15.15	**Expanding the Target Space for Drug Discovery: Target Identification & Validation at Evotec** Dr Eberhard Krauss, Group Leader, Evotec	**A top class European partner for high potent APIs development and manufacturing from early phase to commercialization.** Mr Giorgio Bertolini, SVP R&D, Olon	**Spray drying: a versatile processing technology to stabilise biologics, improve bioavailability whilst controlling particle size.** Dr Andrew Naylor, R&D Director, Upperton Pharma Solutions
15.30 - 16.00		**Refreshments and partnering**	
16.00 – 17.30	**Outsourcing Case Studies.** Chair: Professor Brian Cox, Professor of Pharmaceutical Chemistry, and Co-Director and Co-Founder, Sussex University, and Photodiversity Ltd *Discovery Room*	**Outsourcing Case Studies.** Chair: Dr Frederik Barfoed Beck, Senior Outsourcing Manager, Zealand Pharma *Small Molecule and Plenary Room*	**Outsourcing Case Studies.** Chair: Dr Karlheinz Landaeur, Managing Director, Quality Biotech Development & Cells GmbH *Biologics Room*
16.00	**Discovery & Development of Bicycles, a brand new class of chemically synthesised medicines and the role played by CROs.** Dr Paul Beswick, Director UK Chemistry & IP, Bicycle Therapeutics	**Building an external manufacturing network for Orphan Drug Development.** Bianca Matthee, VP Manufacturing & Pharmaceutics, ProQR	**Logistics as a major player in the supply of personalized therapeutic cancer pDNA vaccines..** Dr Mette Husbyn, CTO, Vaccibody
16.20	**Pushing the boundaries of Biology: Utilising an external research network to develop new assays for Malaria Drug Discovery.** Dr Brice Campo, Director, Discovery Department, Medicines for Malaria Venture	**Balancing Timelines & Ingenuity, A journey Through Case Studies of Life at a Premier CDMO.** Dr Jeorg Jung, Senior Director Custom Synthesis, AMRI	**Strategies towards optimized and flexible facilities for vaccine and biotherapeutic manufacturing.** Sebastian Pungel, Programme Manager, Univercells
16.40	**Medicinal Chemistry on the way to new frontiers – From "Do it all yourself" to a highly integrated Mode of Action.** Dr Werngard Czechtizky, Senior Director, Head Medicinal Chemistry, IMED RIA, AstraZeneca	**Flexibility and agility in collaboration with CDMOs in view of product development and launch.** Dr Rudolf Hausmann, VP Technical Development, Santhera Pharmaceuticals	**Zelluna manufacturing strategy case study.** Dr Arjan Roozen, CTO, Zelluna Immunotherapy
17.00	**Early Form Screening Strategies to Accelerate Candidate Selection.** Prof Chris Frampton, JM Scientific Adviser, Johnson Matthey	**Innovation through partnership in process development and manufacture.** Dr Georg Wuitschik, Senior Scientist, F.Hoffmann-la Roche Ltd & Dr Youchu Wang, Head of Process R&D, Changzhou Site, STA Pharmaceutical, a WuXi AppTec Company	**Hookipa's Supercharged Immunotherapeutics: Sourcing & Project Managing a complex network of external CROs and CMOs** Dr Andreas Aspoeck, Head of External Manufacturing, Hookipa Biotech AG
17.30 - 19.30		**Drinks reception** Basel basel.ch	

Programme BOS 2019 - Day 2

Time	DISCOVERY OUTSOURCING	CMC OUTSOURCING SMALL MOLECULE	CMC OUTSOURCING BIOLOGICS
08.00 - 09.00		**Refreshments and partnering**	
09.00 – 11.00	**Technical Operations Outsourcing – Lead Generation to Lead Optimization** Chair: Dr Neil Press, Diector, Global Discovery Chemistry, Novartis *Discovery Room*	**Technical Operations Outsourcing – Late Phase, Small Molecule** Chair: Dr Yogeshwar Bachhav, Associate Director Pharmaceutical Development, AiCuris GmbH *Small Molecule & Plenary Room*	**Technical Operations Outsourcing – Late Phase, Biologics** Chair: Prof Rolf G. Werner, Professorship for Industrial Biotechnology, Eberhard Karls University of Tuebingen, Germany - *Biologics Room*
09.00	**Premium CRO impact in Agritech: from patent exemplification to process optimization and pilot synthesis.** Dr Florian Guignard, R&D Associate Scientist, AgroSustain & Dr Thomas Fessard, Co-Founder and CEO, SpiroChem	**Utilising biocatalysis and the external workbench to deliver the Roche Small Molecule pipeline.** Dr Dennis Wetzl, Scientist, F. Hoffmann-La Roche Ltd.	**Creating a framework for effective CMO selection for late phase biopharmaceutical drug substance production.** Dr Karlheinz Landaeur, Managing Director, Quality Biotech, QBDC GmbH
09.30	**Unleashing the potential of Biotech through collaborative discovery.** Dr Paul Beswick, Director UK Chemistry & IP, Bicycle Therapeutics & Dr David Madge, VP Research Services Division, WuXi AppTec Inc	**The Onpattro Story: The development and commercialization of a siRNA therapeutic leveraging an outsourcing model.** Dr Charlie Hitscherich, Head of Clinical Supply & External Manufacturing, Alnylam Pharmaceuticals	**Integrated matrix assisted enzymatic antibody drug conjugation.** Prof. Dr. Dr. Rolf G. Werner, Science & Technology Committee, GeneQuantum Healthcare
10.00	**Integrating internal and external expertise and capabilities to drive successful drug discovery and development in a small biotech.** Dr Steve Collingwood, Head of Chemistry, Eneterprise Therapeutics	**Optimised formulation strategies: development of an oral formulation of Edaravone for ALS.** Dr Ronald Van Der Geest, General Partner, 3D-PharmXchange and Chief Development Officer, Treeway	**Biologics outsourcing: preparing for launch readiness with your CMO partner.** Dr Ulrich Rümenapp, Head of Launch Preparation and Co-ordination, Biological Development , Bayer Pharma
10.30	**Phase-appropriate solid form screening in early development.** Mr Matteo Seregni, Business Development Director, Ardena	**High potent API manufacturing at FAREVA.** Dr Christian Miksch, Key Account Manager, Fareva SA / Excella GmbH	**Freeflex®: fill and finish service in innovative IV-bag for global supply.** Dr Benedikt Reichart, Business Development Manager, Fresenius Kabi Austria GmbH
10.45	**Unique nanonisation technology for poorly soluble APIs by Nanoform.** Dr Niklas Sandler, Chief Technology Officer, Nanoform Finland Ltd	**Diazomethane: embracing hazardous chemistry at scale and through the utilisation of flow chemistry.** Dr Dan Stark, Development Chemist, Sterling Pharma Solutions Ltd	**An Agnostic Approach of Applying PAT and Mathematical Modelling to Support Process Knowledge Enhancement.** Dr Nicola Barison, Biologics Technical Lead, APC Ltd.
11.00 - 11.30		**Refreshments & partnering**	
11.30-12.30	**Bridging capability gaps in drug discovery in fibrotic disease: A workshop approach to identify capability gaps and initiate collaborations to bridge these gaps.** Chair: Dr Simon Cruwys, Co-founder and Director, TherapeutAix *Discovery Room*	**Creating the conditions to enable win/win, sustainable outsourcing relationships. In this session we ask the speakers to share their perspectives on how to create effective outsourcing partnerships.** Chair: Dr Anna Matranga, Principal, AMC Alliances & Consulting *Small Molecule & Plenary Room*	
11.30	Panel Members **Bob Humphries**, Director , Project Strategy, TherapeutAix **Dr Darcey Black**, Director, Translational, TherapeutAix **Dr Lyn Rosenbrier Ribeiro,** Expert Network Lead, Virtual R&D, Medicines Discovery Catapult **Dr Jane Escott**, Director, Respiratory External innovation, AstraZeneca	**Developing a supplier governance model as part of an integrated supplier relationship strategy.** Dr Andrea Calenne, Senior Manager Global Strategic Sourcing, Biogen **David and Goliath? Building successful and sustainable collaborations with CMOs - the view from a non-profit SME.** Dr Joan Herbert, Director of Business Development, Medicines for Malaria Venture **Creating the conditions to enable win/win, sustainable outsourcing relationships.** Dr Petra Dieterich, Vice President, Business Development, Evotec	
11.50			
12.10			
12.30 - 14.00		**Lunch & Partnering**	
14.00 – 15.30		**Outsourcing Case Studies:** **Innovator & Sponsor Showcasing Outsourcing Case Studies** Chair: Dr Alexander Bausch, CEO, Strekin - *Small Molecule and Plenary Room*	
14.00		**Fragment based drug discovery partnership for an early phase biotech.** Dr Kamal Azzaoui, CEO, Saverna Therapeutics & Dr Thomas Fessard, Co-Founder and CEO, SpiroChem	
14.30		**Outsourcing strategies for the development of Biosimilars.** Norbert Bleich, CMO/COO, Valerius Biopharma	
15.00		**Collaboration between biotech, consultant and CMO to drive the development and production of a vaccine.** Prof. Dr. Tudor Arvinte, Chairman, CEO, Therapeomics Inc and University of Geneva & Dr Lee Smith, CEO, GreyRigge/ Chief Technology Officer, Themis Biosciences	
15.30		**Conference Close & Drinks Reception**	

Please see floor plan for locations of the break out rooms

Poster Presentation Scheduled for 19th June, 11.00 to 12.00

TIME	Discovery Poster Presentations Chair: Dr Duncan Judd, CEO, Awridian *Discovery Room*	CMC (Small Molecule) Poster Presentations: Chair: Dr David Elder, Principal Consultant, David P Elder Consulting *Small Molecule and Plenary Room*	CMC (Biologics) Poster Presentations: Chair: Dr Lee Smith, CEO, GreyRigge/ Chief Technology Officer, Themis Biosciences *Biologics Room*
11.00 - 11.10	**Non-clinical in vitro ADME Tox services by SOLVO - transporters and more.** Roelof de Wilde, Director of Sales, Solvo Biotechnology	**Development and manufacture of highly potent API drug products throughout the clinical phases.** Mr Wesley Herridge, Senior Pharmaceutical Development Manager, PCI Pharma Services	**Empowering Enzymes for Pharmaceutical Applications** Dr Yves Dudal, Lead Director, Inofea
11.10 - 11.20	**Fast track in Drug Discovery.** Kristina Goncharenko, Business Development Manager, SpiroChem AG	**SK biotek Ireland: Current capabilities to develop, optimize and manufacture highly potent APIs.** Mr Colm Duffy, R&D Products Portfolio Manager, SK biotek Ireland	**Application of MVDA, Raman Spectroscopy and Process Control to Enhance Bioprocess Understanding and Promote Bioprocess Optimization** Mr Mark Sheehan, Research Scientist, APC Ltd.
11.20 - 11.30	**The development of a set of novel small molecule inhibitors of the Kv1.3 ion channel.** Robert Kirk,by, Head of CRO Services, Metrion Biosciences	**Continuous technology improvement: key partnership to meet your outsourcing needs.** Simone Manzini, Business Development Manager, Custom Synthesis, Procos	**This is not just fill finish: insight from a C(D) MO perspective.** Carol Delauney, Director Business Development, Legacy Pharmaceuticals Switzerland GmbH
11.30 - 11.40	**Artificial intelligence applied to biotech.** Dr Fred Jordan, Co-founder and CEO of AlpVision	**An integrated drug development approach: accelerating the path from drug candidates to clinical trials.** Dr Nathalie Huther, Business Development Manager Europe, Arcinova	**Presentation title to be confirmed.** Dr Barry Shortt, Senior Director Global Market Intelligence, CMAB
11.40 - 11.50	**Capture Compound Mass Spectrometry®: on- and off-target deconvolution.** Dr Tammy Ladduwahetty, Group Leader, Medicinal Chemistry, Charles River Laboratories	**Development and scale-up of continuous flow processes for the manufacture of active pharmaceutical ingredients.** Dr Peter Poechlauer, Innovation Manager, API, Patheon	**Speed Matters – Validated Manufacturing Cell Line in 8 Weeks.** Iris Bodenmann, Cell Line Development Engineer, Selexis SA
11.50 - 12.00	**Digitalisation of research outsourcing – creating faster science.** Tom Dexter, VP, Scientist.com	**Rational Design of Enabling Platforms: from API to Amorphous Solid Dispersion based Tablets.** Dr Paulo Lino, Scientist, Hovione	**Q&A for Biologics Poster presenters**

Featured Posters 2019

DISCOVERY

The development of a set of novel small molecule inhibitors of the Kv1.3 ion channel Metrion Biosciences

Ion channels represent 15-20% of historic drug approvals but are notoriously complex targets and require specialised screening technology such as automated patch clamp (APC) electrophysiology. We outline a situation where a pharma company turns to a specialist CRO to fill their knowledge gap. During the collaboration, we developed potent and selective Kv1.3 modulators with nM efficacy against human T-cells and potential to treat auto-immune disease.

SMALL MOLECULES & BIOLOGICS

Demand for Biotech packaging drives significant PCI investment at multiple locations world wide PCI Pharma Services

PCI recognise that biologically derived therapeutic products are the new frontier, heralding revolutionary treatments of a number of diseases and injuries. We have committed to a $20m investment in support of biologic medicines and advanced injectable delivery forms. Expanding our Biotech clinical and commercial packaging and release testing capability at our Centre of Excellence in Philadelphia, as well as expanded Cold Chain capacity at numerous global locations.

BIOLOGICS

Application of MVDA, Raman Spectroscopy and Process Control to enhance bioprocess understanding

Chinese Hamster Ovary cells are the most widely-used platform for the production of monoclonal antibodies (mAbs) by the biopharmaceutical sector. CHO cell mAb manufacturing processes require refinement to ensure that the highest product yield is achieved while ensuring quality. The use of Process Analytical Technology (PAT), such as Raman spectroscopy, enables in-depth interrogation of cell culture operations in order to define optimal feeding and control strategies.

Biotech Outsourcing Strategies:
Facilitating partnering between Contract Giver and Contact Acceptor

BOS Outsourcing Partnering Dynamic

CONTRACT GIVER *(Biotech/Pharma)*	CONTRACT ACCEPTOR *(CMO/CRO)*
• Outsourcing Requirements	• Supply of Outsourcing Services & Technologies
• Technology/Capabilities Scouting	• New Technology & Innovation Development
• Relationship Management	• Account Management

BOS Event Components Delivering Partnering & Matchmaking

BOS PARTNERING SOFTWARE

All attendees will have access to the BOS Partnering Software. This platform allows participants to contact one another prior to the event to arrange 1-to-1 meetings. Confirmed meeting will then be scheduled into your agenda during the event. Further details describing this process are provided below:

Step 1: 4 weeks prior to the event, Biotech & Pharma participants (Contract Giver) invited to access the Partnering software and outline outsourcing requirements e.g. Looking for aseptic fill and finish capabilities.

Step 2: 3 weeks prior to the event, CRO and CMO participants receive credentials to access the partnering and are invited to outline outsourcing capabilities and 1-to-1 meeting objectives

Step 3: 3 weeks – 1 day prior to event. Partnering software fully operational. Delegates can use the software to send meeting requests, based on a specific timeslot, to a fellow delegate who can then accept or decline the meeting request.

Step 4: Accepted meeting requests will be scheduled in your agenda at the requested timeslot. You will be able to view your finalised 1-to-1 meeting agenda electronically.

Step 5: Go to the allocated partnering table (as shown on your agenda) or exhibitor stand at the specified time to conduct your 1-to-1 meeting

BOS Events are built around the exhibition space. Our venue has been carefully selected to offer an "open plan" space, which allows exhibiting CROs and CMOs the opportunity to present the full breadth of their capabilities to the attending biotech and pharma community. See details of the floor plan below.

CRO & CMO EXHIBITION



BOS BASEL 2019 : Stand Reservations

Stand 1 **Patheon**
Stand 2 **Bio2Business**
Stand 6 **APC**
Stand 7 **Evotec**
Stand 8 **CatSci**
Stand 9 **Intertek**
Stand 10 **scientist.com**
Stand 12 **Syngene International**
Stand 15 **Alcami**
Stand 16 **Upperton**
Stand 17 **MercachemSyncom**
Stand 18 **Fresenius Kabi Germany**
Stand 19 **Navin Flourine**
Stand 20 **Asymchem**
Stand 21 **Bioassay Online**
Stand 22 **SK Biotek**
Stand 23 **Quay Pharmaceuticals**
Stand 24 **Sterling Pharma Solutions**
Stand 25 **Acino International**
Stand 26 **anaRIC biologics**
Stand 27 **Johnson Matthey**
Stand 28 **Olon**
Stand 29 **Ajinomoto Biopharma**
Stand 30 **MedPharm**
Stand 31 **CARBOGEN AMCIS**
Stand 32 **Eurofins CDMO**
Stand 33 **Minakem**
Stand 34 **Fareva**
Stand 35 **AMRI**
Stand 36 **Hovione**
Stand 37 **Almac Group**
Stand 38 **Cambrex**
Stand 39 **Solvias**
Stand 40 **PCI Pharma Services**
Stand 41 **Quality Assistance**
Stand 42 **LGC**
Stand 43 **Alderley Analytical**
Stand 44 **FARMHISPANIA GROUP**
Stand 45 **Research Toxicology Centre**
Stand 46 **AlpVision**
Stand 47 **Ardena**
Stand 48 **Nanoform Finland**
Stand 49 **Particle Analytical**
Stand 50 **Inofea**
Stand B1 **Holodiag**
Stand B2 **Recipharm**
Stand B3 **Legacy Pharma**
Stand B4 **Concept Life Sciences**
Stand B5 **PolyCrystalLine**

"For anacura the BOS Basel 2018 event was an excellent opportunity to meet customers and to connect with new prospects. Both size and focus of the event were excellent for this purpose. The presentations and the partnering tool were most helpful to connect with CMC professionals and discuss new trends, developments and needs in the field of CMC analytics for DS and DP including small molecules, biologics and cell based medicinal therapies. I am looking forward to the 2019 event."

Eddy Ruijter, Business Development Manager, anacura

"BOS Basel 2018 was a success as it provided the opportunity to introduce ProQR Therapeutics NV, gave the forum to network with existing CDMO's and get in-touch with new CDMO's and (re-) connect with CMC colleagues in the pharma industry."

Maarten Van Geffen, Senior Director, Clinical Supplies & Logistics, ProQR Therapeutics

"The expansion to discovery has broadened the conference and have brought in a complementary focus."

Dr Alexander Bausch, CEO, Strekin AG

Go to http://www.bio2bevents.com/registration to complete your registration enquiry online

Key CRO Sponsors

Gold Sponsors

Exhibition Sponsors

Silver Sponsors

Host Sponsors

Events Partners

Basel
basel.ch